Yahoo Finance

Morgan Stanley lowered the firm’s price target on NeoGenomics (NEO) to $10 from $17 and keeps an Equal Weight rating on the shares. The company’s Q1 miss was primarily driven by lower non-clinical revenue and lower than expected average unit price, says the analyst, who sees “more questions than answers” following the company’s quarterly report.

Protect Your Portfolio Against Market Uncertainty

• Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.

• Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on NEO:

Disclaimer & DisclosureReport an Issue

• NeoGenomics price target lowered to $12 from $17 at TD Cowen

• NeoGenomics price target lowered to $10 from $12 at BofA

• NeoGenomics price target lowered to $12 from $17 at BTIG

• NeoGenomics: Hold Rating Amid Mixed Financial Performance and Market Conditions

• NeoGenomics Reports Strong Q1 2025 Performance